Document
Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization : first report from the Sultanate of Oman.
Contributors
Al-Kharousiyah, Nadia., Author
Hamood, Harith., Author
Publisher
Oman Medical Specialty Board.
Gregorian
2008-10
Language
English
English abstract
Background: Central Serous Chorioretinopathy (CSCR) is
characterized by accumulation of subretinal fluid, resulting in
neurosensory retinal detachment.
Design: Interventional study.
Methods: Five patients (CSCR-3; Idiopathic-2) with Choroidal
Neovascularization (CNV) were selected for the study. All
patients had Standardized refraction, color photographs,
fluorescein angiography (FA), and Photodynamic Therapy (PDT)
using verteporfin. Optical Coherence Tomography (OCT)
was done wherever applicable. The main outcome measures
were improvement or stability in Best Corrected Visual Acuity
(BCVA) and FA identified closure of lesions.
Results: Followup period for the CSCR group ranged from 8 to
11 months and for the idiopathic group 12 to 23 months. BCVA
improved in 67% eyes in the CSCR group (three eyes). Amongst
the idiopathic group (two eyes), one eye gained BCVA by two
lines while the other lost one Snellen line from baseline VA. FA
identified CNV lesions closed in 67% eyes in the CSCR group
and all eyes in the idiopathic CNV group.
Conclusions: Photodynamic therapy with Verteporfin can be an
ideal mode of therapy in chronic CSCR with or without CNV,
and idiopathic CNV in terms of improved or stabilized VA, and
closure of the CNV lesions. A study involving a larger number
of patients as a multicenter trial would add to the authenticity of
our observation.
Member of
Resource URL
Citation
Wali, Upender Krishen, Al-Kharousiyah, Nadia, & Hamood, Harith (2008). Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization : first report from the Sultanate of Oman. Oman Medical
Category
Journal articles